Federal Court Scrutinizes Amgen’s Urgency in Biosimilar Appeal Against Regeneron

In a recent hearing, a Federal Circuit judge engaged in a dialogue with Amgen’s counsel regarding the urgency of an appeal process on a previously denied injunction. This injunction pertains to Regeneron’s biosimilar version of Eylea, a treatment for macular degeneration. The judge openly questioned the motives behind the attorney’s urgency in hastening the appeal, highlighting a point of contention over procedural pace. This ongoing legal tussle reflects the tense landscape in the pharmaceutical industry over biosimilars and their market entry. For further details, visit the full article.